The Institute for Clinical and Economic Review (ICER) on Thursday, March 14, released a draft evidence report on Novartis’s siponimod for the treatment of secondary progressive multiple sclerosis.
According to a press release, the report is open to public comment until 5 p.m. EST April 10. ICER is planning to publish an evidence report on the therapy May 2.
The Food and Drug Administration is expected to make a decision on siponimod some time this month.
To read ICER’s draft evidence report, click here.